Literature DB >> 29908980

Incidence and Prognostic Significance of Carcinoid Lymph Node Metastases.

Peter J Kneuertz1, Mohamed K Kamel2, Brendon M Stiles2, Benjamin E Lee2, Mohamed Rahouma2, Sebron W Harrison2, Nasser K Altorki2, Jeffrey L Port3.   

Abstract

BACKGROUND: Pulmonary carcinoid tumors are often considered indolent tumors. The prognostic significance of lymph node (LN) metastases and the need for mediastinal dissection is controversial. We sought to determine the incidence, risk factors, and prognosis of LN metastases in resected carcinoid patients.
METHODS: Patients undergoing lung resection for carcinoid and removal of ≥10 LNs were identified in the National Cancer Database from 2004 to 2014. Typical (TCs) and atypical carcinoids (ACs) were included. Clinical and pathologic LN status was assessed. Overall survival (OS) was analyzed using log-rank test and Cox hazard regression analysis.
RESULTS: A total of 3,335 patients (TC 2,893; AC 442), underwent resection (lobectomy/bilobectomy 84%, pneumonectomy 8%, sublobar resection 8%). LN involvement was present in 21% of patients (N1 15%, N2 6%) and increased with tumor size and AC histology. Tumor size was an independent predictor of LN disease. The rate of nodal upstaging was 13% (TC 11%, AC 24%). Independent predictors of OS were AC type (HR 3.25 [95% CI 2.19-4.78]) and LN metastases (HR 2.3 [1.49-3.58]). LN disease was associated with worse survival for TC > 2 cm (5-year OS 87% versus 94%, p = 0.005) and AC (58% versus 88%, p = 0.001), but not for small (≤ 2 cm) TC patients (5-year OS 93% versus 92%, p = 0.67).
CONCLUSIONS: A substantial number of well-staged carcinoid patients had LN metastases. Large tumor size is a valuable predictor of carcinoid nodal disease. LN involvement was an independent predictor of worse survival. Nodal dissection in tumors > 2 cm and in atypical subtype can yield important prognostic information.
Copyright © 2018 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29908980     DOI: 10.1016/j.athoracsur.2018.05.044

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  15 in total

1.  SURGICAL APPROACH OF LUNG CARCINOID TUMORS.

Authors:  C E Nistor
Journal:  Acta Endocrinol (Buchar)       Date:  2022 Apr-Jun       Impact factor: 1.104

Review 2.  Surgical Principles in the Management of Lung Neuroendocrine Tumors: Open Questions and Controversial Technical Issues.

Authors:  Debora Brascia; Giuseppe Marulli
Journal:  Curr Treat Options Oncol       Date:  2022-10-21

3.  Long-term survival analysis of sublobar resection versus lobectomy for older patients with early-stage pulmonary carcinoid tumour: a database-based propensity score-matched study.

Authors:  Hao Yang; Xinqi Xiao; Tonghua Mei; Ping Zhou
Journal:  Aging Clin Exp Res       Date:  2022-03-28       Impact factor: 4.481

4.  Examination of factors associated with lymph node metastases in lung carcinoids: Results from a single institution retrospective cohort study.

Authors:  Mythili P Pathipati; Thomas K Yohannan; Lu Tian; Kathleen Hornbacker; Jalen A Benson; Gerald J Berry; Natalie S Lui; Pamela L Kunz; Sukhmani K Padda
Journal:  Lung Cancer       Date:  2021-01-23       Impact factor: 5.705

5.  New TNM staging in lung cancer (8th edition) and future perspectives.

Authors:  José-María Matilla; M Zabaleta; E Martínez-Téllez; J Abal; A Rodríguez-Fuster; J Hernández-Hernández
Journal:  J Clin Transl Res       Date:  2020-09-02

6.  Prognostic nomogram for predicting long-term cancer-specific survival in patients with lung carcinoid tumors.

Authors:  Yanqi He; Feng Zhao; Qingbing Han; Yiwu Zhou; Shuang Zhao
Journal:  BMC Cancer       Date:  2021-02-08       Impact factor: 4.430

7.  The Outcome of Primary Hepatic Carcinoid Tumor: A Retrospective Study Based on Propensity Score Matched Survival Analysis.

Authors:  Shaotao Jiang; Huijie Wu; Rongdang Fu; Jialuo Mai; Jiyou Yao; Xuefeng Hua; Huan Chen; Jie Liu; Minqiang Lu; Ning Li
Journal:  Front Oncol       Date:  2021-02-24       Impact factor: 6.244

Review 8.  Molecular Pathology of Well-Differentiated Pulmonary and Thymic Neuroendocrine Tumors: What Do Pathologists Need to Know?

Authors:  Marco Volante; Ozgur Mete; Giuseppe Pelosi; Anja C Roden; Ernst Jan M Speel; Silvia Uccella
Journal:  Endocr Pathol       Date:  2021-02-27       Impact factor: 3.943

9.  Nodal Upstaging Evaluation After Robotic-Assisted Lobectomy for Early-Stage Non-small Cell Lung Cancer Compared to Video-Assisted Thoracic Surgery and Thoracotomy: A Retrospective Single Center Analysis.

Authors:  Filippo Tommaso Gallina; Enrico Melis; Daniele Forcella; Edoardo Mercadante; Daniele Marinelli; Serena Ceddia; Federico Cappuzzo; Sabrina Vari; Fabiana Letizia Cecere; Mauro Caterino; Antonello Vidiri; Paolo Visca; Simonetta Buglioni; Isabella Sperduti; Mirella Marino; Francesco Facciolo
Journal:  Front Surg       Date:  2021-07-01

10.  Characterization of Outcomes by Surgical Management of Lung Neuroendocrine Tumors Associated With Cushing Syndrome.

Authors:  Kenneth P Seastedt; George A Alyateem; Karthik Pittala; Seth M Steinberg; David S Schrump; Lynnette K Nieman; Chuong D Hoang
Journal:  JAMA Netw Open       Date:  2021-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.